Regeneron Pharmaceuticals, Inc. (REGN)

562.00
3.20 0.56
NASDAQ
Prev Close 565.19
Open 561.00
Day Low/High 555.57 / 564.99
52 Wk Low/High 271.37 / 664.64
Volume 113.24K
Exchange NASDAQ
Shares Outstanding 106.39B
Market Cap 60.80B
P/E Ratio 22.15
Div & Yield N.A. (N.A)
Jim Cramer: Here Are the Quarter's Winners, Losers

Jim Cramer: Here Are the Quarter's Winners, Losers

The five best performing and worst performing stocks in the S&P 500 in the previous quarter pretty much tells the tale of the tape, so here goes.

Jim Cramer: Here's the Science Behind Our Rally

Jim Cramer: Here's the Science Behind Our Rally

While Johnson & Johnson and other pharma cos. give us hope, here's my wish list to keep the nation safe and the economy ready to go again.

Sanofi's Charts Show Upside Potential Amid Its Covid-19 Work

Sanofi's Charts Show Upside Potential Amid Its Covid-19 Work

The drug and vaccine maker possibly could see its shares double according to a key chart.

Jim Cramer: The Rescue Bill and a Fed Dive-Bombing Policy Ignited All Sectors

Jim Cramer: The Rescue Bill and a Fed Dive-Bombing Policy Ignited All Sectors

I think our scientists, our medical minds, are working on an atomic bomb that can nuke Covid before it invades us.

Failed Rallies, Semiconductors Rising and the Fed's Big Guns

Failed Rallies, Semiconductors Rising and the Fed's Big Guns

The Fed has attacked developing problems in real-time -- and as China shows signs of life, the semi stocks are benefitting.

The Fed's Big Bazooka, Covid-19 Treatments, Market Breather

The Fed's Big Bazooka, Covid-19 Treatments, Market Breather

Amid dramatically rising jobless claims, the Fed continues to fire big bullets, the Senate is pushing its economic support package and Gilead and Regeneron have made progress on coronavirus treatments.

These Are the Times We Live In

These Are the Times We Live In

Here again is my approach and my three stock groups: 'rebound', 'revenue' and 'virus'.

Regeneron Pharmaceuticals Could Be a Bright Spot in a Sea of Declines

Regeneron Pharmaceuticals Could Be a Bright Spot in a Sea of Declines

We looked at the charts of REGN yesterday but with things (read: stock prices) changing so fast it wouldn't hurt to look again.

The Magic Mice of Regeneron

The Magic Mice of Regeneron

I am pretty well covered in my 'virus group'. I could definitely see bringing a few shares of REGN on board the next time the algorithms include that name in a broad selloff. Not before.

Regeneron Pharmaceuticals Presents Bullish Charts Amid Covid-19 Work

Regeneron Pharmaceuticals Presents Bullish Charts Amid Covid-19 Work

The biopharma giant's work on a coronavirus antibody treatment is helping move its shares in a different direction than the market has taken.

5 Leading Biotechs in Search of a Coronavirus Vaccine

5 Leading Biotechs in Search of a Coronavirus Vaccine

The race is on. The prize could be countless lives saved and perhaps billions of dollars in revenue.

This Stock Is Standing Up to the Correction Like Few Others

This Stock Is Standing Up to the Correction Like Few Others

Biotech name has bolted higher with some amazing relative strength.

Real Money Post Industrial Average Holds Own Amid Covid-19 Selloff

Real Money Post Industrial Average Holds Own Amid Covid-19 Selloff

Amid a flood of corporate warnings over the coronavirus, all the major stock market indexes finished last month down 6.4% to 10.1%.

Jim Cramer: Rate Cut No Cure for Coronavirus

Jim Cramer: Rate Cut No Cure for Coronavirus

But don't throw up your arms yet -- here are names that could be golden opportunities.

Regeneron's Pullback Amid Market Weakness Could Lead to Buying Opportunity

Regeneron's Pullback Amid Market Weakness Could Lead to Buying Opportunity

The biopharma giant could fall further, so wait for a candlestick reversal pattern before going long.

Regeneron Pharmaceuticals Could Surprise on the Upside With Its Quant Buy Signal

Regeneron Pharmaceuticals Could Surprise on the Upside With Its Quant Buy Signal

Are the technical and quantitative approaches on the same page?

RMPIA Lags in November, but Trounces S&P 500 for Quarter, Year So Far

RMPIA Lags in November, but Trounces S&P 500 for Quarter, Year So Far

Now, many Real Money Post Industrial Average stocks should see a boost from the holiday splurge by shoppers.

Real Money Post Industrial Average Exits October on Top

Real Money Post Industrial Average Exits October on Top

The RMPIA's 3.8% jump even beat the Nasdaq Composite Index's 3.7% October climb.

Regeneron Has That 'Look' to It Again

Real Money Post-Industrial Average Continues to Outpace Major Indices

Real Money Post-Industrial Average Continues to Outpace Major Indices

RMPIA is up 20.9% in the first nine months of 2019.

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.

Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019

Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019

There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.

2 Well-Known Stocks You Should Consider Shorting This Week

2 Well-Known Stocks You Should Consider Shorting This Week

These bearish bets are showing both technical and quantitative deterioration.

A Six-Pack of Biotech Best Bets

A Six-Pack of Biotech Best Bets

Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.

Real Money Post-Industrial Average Leaves Major Indices in the Dust

Real Money Post-Industrial Average Leaves Major Indices in the Dust

RMPIA outperformed once gain during April.

A Bullish Play on Netflix

A Bullish Play on Netflix

Netflix is bullish, but faces key resistance before it can make a big run higher.

Stalking an Entry in Regeneron Pharmaceuticals

Stalking an Entry in Regeneron Pharmaceuticals

A low-risk countertrend options trade may be worth a look in this name.